CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for CytoMed Therapeutics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

CytoMed Therapeutics Ltd
#08-22 One Commonwealth
1 Commonwealth Lane
Phone: +65 603824911p:+65 603824911 149544  Singapore Ticker: GDTCGDTC
Business Summary
CytoMed Therapeutics Limited is a pre-clinical biopharmaceutical company. The Company is focused on harnessing its licensed proprietary technologies to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies, as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. It is developing three product candidates: CTM-N2D, iPSC-gdNKT and CTM-GDT. CTM-N2D is its lead product candidate, and it consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. Its second product candidate, iPSC-gdNKT, utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. Its third product candidate, CTM-GDT, consists of expanded allogeneic gamma delta T cells.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202212/31/2022YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Chee KongChoo 64 3/1/2018 3/1/2018
Chief Financial Officer YvonneGoh 34 3/1/2020 3/1/2020
Chief Operating Officer, Director Wee KiatTan 35 4/18/2023 2/1/2019
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 28 (As of 12/31/2022)
Outstanding Shares: 11,540,000 (As of 4/22/2024)
Stock Exchange: NASD


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 28, 2024